These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 24654220)

  • 21. Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose.
    Mercadante S; Ferrera P; Adile C; Casuccio A
    J Pain Symptom Manage; 2011 Sep; 42(3):464-9. PubMed ID: 21477977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of opioids in the treatment of chronic non-cancer pain.
    Trescot AM; Glaser SE; Hansen H; Benyamin R; Patel S; Manchikanti L
    Pain Physician; 2008 Mar; 11(2 Suppl):S181-200. PubMed ID: 18443639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence and predictors of cognitive dysfunction in opioid-treated patients with cancer: a multinational study.
    Kurita GP; Sjøgren P; Ekholm O; Kaasa S; Loge JH; Poviloniene I; Klepstad P
    J Clin Oncol; 2011 Apr; 29(10):1297-303. PubMed ID: 21357785
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain.
    Davies A; Sitte T; Elsner F; Reale C; Espinosa J; Brooks D; Fallon M
    J Pain Symptom Manage; 2011 Feb; 41(2):358-66. PubMed ID: 21334555
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study.
    Sittl R; Nuijten M; Nautrup BP
    Clin Ther; 2005 Jul; 27(7):1022-31. PubMed ID: 16154481
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period.
    Kress HG; Orońska A; Kaczmarek Z; Kaasa S; Colberg T; Nolte T
    Clin Ther; 2009 Jun; 31(6):1177-91. PubMed ID: 19695386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and genetic factors related to cancer-induced bone pain and bone pain relief.
    Scarpi E; Calistri D; Klepstad P; Kaasa S; Skorpen F; Habberstad R; Nanni O; Amadori D; Maltoni M
    Oncologist; 2014 Dec; 19(12):1276-83. PubMed ID: 25342315
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain.
    van Seventer R; Smit JM; Schipper RM; Wicks MA; Zuurmond WW
    Curr Med Res Opin; 2003; 19(6):457-69. PubMed ID: 14594516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of sublingual fentanyl vs. oral morphine for cancer-related breakthrough pain.
    Velázquez Rivera I; Muñoz Garrido JC; García Velasco P; España Ximénez de Enciso I; Velázquez Clavarana L
    Adv Ther; 2014 Jan; 31(1):107-17. PubMed ID: 24385406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies.
    Davies A; Zeppetella G; Andersen S; Damkier A; Vejlgaard T; Nauck F; Radbruch L; Sjolund KF; Stenberg M; Buchanan A
    Eur J Pain; 2011 Aug; 15(7):756-63. PubMed ID: 21251860
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain.
    Rauck RL; Tark M; Reyes E; Hayes TG; Bartkowiak AJ; Hassman D; Nalamachu S; Derrick R; Howell J
    Curr Med Res Opin; 2009 Dec; 25(12):2877-85. PubMed ID: 19814586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pain levels within 24 hours after UFE: a comparison of morphine and fentanyl patient-controlled analgesia.
    Kim HS; Czuczman GJ; Nicholson WK; Pham LD; Richman JM
    Cardiovasc Intervent Radiol; 2008; 31(6):1100-7. PubMed ID: 18797963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prolonged-release oxycodone/naloxone in nonmalignant pain: single-center study in patients with constipation.
    Gatti A; Casali M; Lazzari M; Tufaro G; Gafforio P; Silvestri C; Marcassa C; Sabato AF
    Adv Ther; 2013 Jan; 30(1):41-59. PubMed ID: 23269562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methadone: an effective alternative to morphine for pain relief in cancer patients.
    Shelton BW; Deynes-Romero J; Tofani-Montalvo M; Ramírez-Rivera J; Jaumne-Anselmi F
    Bol Asoc Med P R; 2008; 100(3):7-10. PubMed ID: 19227708
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Three cases of cancer-related pain for which oxycodone injection was efficacious].
    Shinozaki K; Nitta T; Yamauchi M; Doi M
    Gan To Kagaku Ryoho; 2013 Jan; 40(1):119-23. PubMed ID: 23306933
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evolving knowledge of opioid genetics in cancer pain.
    Droney J; Riley J; Ross JR
    Clin Oncol (R Coll Radiol); 2011 Aug; 23(6):418-28. PubMed ID: 21612899
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence of constipation associated with long-acting opioid therapy: a comparative study.
    Staats PS; Markowitz J; Schein J
    South Med J; 2004 Feb; 97(2):129-34. PubMed ID: 14982259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modelling the PKPD of oxycodone in experimental pain - Impact of opioid receptor polymorphisms.
    Olsen R; Foster DJ; Upton RN; Olesen AE; Ross JR; Droney J; Sato H; Drewes AM; Kreilgaard M
    Eur J Pharm Sci; 2016 Apr; 86():41-9. PubMed ID: 26946441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oxycodone-induced analgesic effects in a bone cancer pain model in mice.
    Kato A; Minami K; Ito H; Tomii T; Matsumoto M; Orita S; Kihara T; Narita M; Suzuki T
    Oncology; 2008; 74 Suppl 1():55-60. PubMed ID: 18758199
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Opioids in pain management of mesothelioma and lung cancer patients.
    Salminen EK; Silvoniemi M; Syrjänen K; Kaasa S; Kloke M; Klepstad P
    Acta Oncol; 2013 Jan; 52(1):30-7. PubMed ID: 23025295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.